Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib and Dostarlimab in HRD Solid Tumors
NCT04983745Phase 2Recruiting
- Sponsor
- West Cancer Center & Research Institute
- Start
- Nov 2021
- Primary completion
- Aug 2024
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of niraparib and dostarlimab in solid tumor, sponsored by West Cancer Center & Research Institute. Primary endpoint: Objective Response Rate at 2 years. Started Nov 2021; status: recruiting.
02
Drugs
niraparibdostarlimab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04983745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04983745.